Attached files
file | filename |
---|---|
EX-23.3 - EX-23.3 - Centessa Pharmaceuticals plc | d123754dex233.htm |
EX-23.1 - EX-23.1 - Centessa Pharmaceuticals plc | d123754dex231.htm |
EX-5.1 - EX-5.1 - Centessa Pharmaceuticals plc | d123754dex51.htm |
S-1MEF - S-1MEF - Centessa Pharmaceuticals plc | d123754ds1mef.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Centessa Pharmaceuticals plc:
We consent to the use of our report dated March 12, 2021, with respect to the combined balance sheets of the Centessa Predecessor Group (consisting of Z Factor Limited, LockBody Therapeutics Ltd, and Morphogen-IX Limited) as of December 31, 2019 and 2020, the related combined statements of operations and comprehensive loss, convertible preferred shares and combined deficit, and cash flows for the years then ended, and the related notes, incorporated herein by reference and to the reference to our firm under the heading Experts in the prospectus.
/s/ KPMG LLP
Boston, Massachusetts
May 27, 2021